Bimagrumab

Drug Profile

Bimagrumab

Alternative Names: BYM-338

Latest Information Update: 11 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MorphoSys; Novartis
  • Developer Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action Type II-B activin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inclusion body myositis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cachexia; Muscular atrophy; Type 2 diabetes mellitus
  • Discontinued Inclusion body myositis

Most Recent Events

  • 21 Apr 2018 Adverse events and efficacy data from an extension study of the phase III RESILIENT trial in Inclusion body myositis presented at the 70th Annual Meeting of the American Academy of Neurology (AAN-2018)
  • 09 Jun 2017 Adverse events and pharmacodynamics data from a clinical trial in Healthy volunteers presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 13 Feb 2017 Novartis completes a phase IIb/III extension trial for Inclusion body myositis (In adults, In the elderly) in USA, Australia, Japan, Belgium, Denmark, Italy, Netherlands, United Kingdom, Switzerland and France (IV) (NCT02573467)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top